Alcoholic Hepatitis

Alcoholic Hepatitis

Definition

Alcohol-associated hepatitis (AAH), formerly called alcoholic hepatitis, is an acute inflammatory liver injury occurring in patients with prolonged heavy alcohol consumption .It represents the most severe manifestation of alcohol-associated liver disease (ALD) and carries a high short-term mortality.

Table of Contents

Spectrum of Alcohol-Associated Liver Disease

Stage	Reversibility	Clinical Significance
Hepatic steatosis	Completely reversible	Earliest stage,Usually asymptomatic,hepatomegaly
Alcohol-associated steatohepatitis	Potentially reversible	Jaundice, fever, anorexia, tender hepatomegaly, weight loss
Fibrosis	Partially reversible	Progressive scarring
Cirrhosis	Usually irreversible	Portal hypertension and liver failure
Decompensated cirrhosis	Irreversible	Ascites, variceal bleeding, encephalopathy
Hepatocellular carcinoma	Malignancy	Can occur with or without cirrhosis

Alcoholic steatohepatitis (ASH) and alcoholic hepatitis (AH) are not same . About 20% to 40% of those who drink alcohol in heavy amounts and have fatty liver eventually develop liver inflammation, which is known as ASH. ASH is a diagnosis based on liver histology, while AH is a clinical diagnosis.

Epidemiology

Occurs in 10–35% of heavy drinkers
Usually(not always take that much time) develops after:

5 years heavy alcohol use,Often >10 years
but it can occur after shorter periods of intense exposure (e.g., >6 months). Patients may stop drinking days or weeks prior to admission, because they feel too ill to drink.

Average alcohol intake

Men: >60–80 g/day
Women: >40–60 g/day

Peak age-40–60 years
Male predominance
Women develop disease with lower alcohol exposure because of lower gastric alcohol dehydrogenase activity.

Risk Factors

Alcohol-Related Factors	Patient-Related Factors	Genetic Factors
Daily heavy alcohol consumption	Female sex	PNPLA3 (I148M) mutation
Continuous alcohol consumption	Malnutrition	TM6SF2 (E167K) mutation
Binge drinking superimposed on chronic alcohol use	Obesity	MBOAT7 polymorphism
Drinking despite established cirrhosis	Smoking
Early age of alcohol initiation	Diabetes mellitus
Large lifetime cumulative alcohol intake	Genetic susceptibility / Family history

Pathogenesis

Alcoholic hepatitis results from multiple simultaneous mechanisms.

Pathogenic Mechanism	Key Events / Effects
Ethanol metabolism	Alcohol → ADH → Acetaldehyde → ALDH → Acetate; acetaldehyde causes hepatocyte injury via protein adducts and oxidative damage.
Oxidative stress	Alcohol induces CYP2E1, generating ROS → lipid peroxidation, mitochondrial dysfunction, and hepatocyte apoptosis.
Gut dysbiosis	Increased intestinal permeability allows LPS endotoxin translocation, activating Kupffer cells.
Cytokine storm	Kupffer cells release TNF-α, IL-1β, IL-6, IL-8, MCP-1 → neutrophilic inflammation, hepatocyte necrosis, cholestasis, and fibrosis.
Neutrophil recruitment	Massive neutrophilic infiltration; release of elastase, myeloperoxidase, and ROS amplifies liver injury.
Adaptive immunity	Alcohol-induced neoantigens activate T cells, causing immune-mediated hepatocyte injury.
Impaired liver regeneration	Suppression of hepatic progenitor cells and hepatocyte proliferation leads to poor liver repair despite alcohol cessation.

Histopathology of ASH

Histopathological Feature	Description
Ballooning degeneration	Large swollen hepatocytes
Mallory-Denk bodies	Aggregates of damaged cytokeratin filaments
Neutrophilic infiltration	Around ballooned hepatocytes; highly characteristic
Steatosis	Usually macrovesicular
Pericellular fibrosis	“Chicken-wire fibrosis”
Cholestasis	Common in severe disease
Megamitochondria	Seen in some patients

Clinical Presentation

Usually develops over—Days,Weeks

Symptoms

Progressive jaundice
Fever
Malaise—Fatigue
Weight loss—Anorexia
Nausea—Vomiting
Right upper quadrant pain

Physical Findings

Tender hepatomegaly
Jaundice—Ascites
Spider angioma—Palmar erythema(alcoholic cirrhosis)
Muscle wasting
Hepatic encephalopathy(ACLF)
Peripheral edema
Fever—Tachycardia

Alcoholic hepatitis and alcoholic cirrhosis overlap to a large extent (and may coexist). Management is generally similar, but alcoholic hepatitis is potentially an indication for steroids.
Alcoholic hepatitis may manifest with multi-organ dysfunction due to ACLF.

Investigations

Laboratory Parameter	Typical Findings
Liver enzymes	AST ↑↑↑, ALT ↑(the rise is usually less than AST because alcohol causes pyridoxal-5′-phosphate (vitamin B6) deficiency, reducing ALT activity.), AST/ALT ratio >2, AST rarely >500 IU/L, ALT rarely >300 IU/L; transaminases >500 IU/L suggest another diagnosis (e.g., ischemic or viral hepatitis).
Bilirubin	Usually >3 mg/dL; often 10–30 mg/dL
INR	Prolonged-Reduced hepatic synthesis of clotting factors (II, V, VII, IX, X) and impaired vitamin K utilization in cholestasis.
Albumin	Low
CBC	Leukocytosis, neutrophilia, macrocytosis (MCV ↑), thrombocytopenia
Hemoglobin ↓	Gastrointestinal bleeding, folate deficiency, bone marrow suppression, nutritional deficiency, or hypersplenism.
Leukocytosis	Common in alcohol-associated hepatitis due to systemic inflammatory response and neutrophilic inflammation; infection should also be excluded.
Leukopenia	Bone marrow suppression, hypersplenism, or advanced cirrhosis.
Macrocytosis (MCV >100 fL)	Direct toxic effect of alcohol on bone marrow, folate deficiency, and altered erythrocyte membrane lipids. May occur even without anemia.
Platelet count ↓	Portal hypertension causes splenic sequestration (hypersplenism); alcohol can also directly suppress bone marrow.
Hyponatremia	Dilutional hyponatremia due to portal hypertension, non-osmotic vasopressin release, and water retention in decompensated cirrhosis.
Hypoglycemia	Impaired hepatic glycogen stores and reduced gluconeogenesis in advanced liver failure; alcohol also inhibits gluconeogenesis.
Other	GGT elevated, ALP mildly elevated, creatinine may rise due to acute kidney injury or hepatorenal syndrome,Carbohydrate-deficient transferrin is the most reliable marker of chronic alcoholism.
Abdominal imaging	exclude biliary obstruction and liver diseases such as hepatocellular carcinoma and liver abscess.Ultrasound is the first imaging test of choice

1. Abdominal Ultrasound (First-Line Investigation)

Typical Findings

Fatty Liver

Increased hepatic echogenicity (“bright liver”)
Hepatomegaly

Cirrhosis

Nodular liver surface
Coarse heterogeneous echotexture
Irregular liver margins

Portal Hypertension

Splenomegaly
Ascites
Dilated portal vein
Recanalized paraumbilical vein
Portosystemic collateral vessels

2. Doppler Ultrasound

Findings

Portal vein diameter >13 mm
Reduced portal vein flow velocity
Hepatofugal (reversed) portal flow in advanced disease
Portal vein thrombosis
Hepatic vein abnormalities

3. Transient Elastography (FibroScan)

Limitations

Liver stiffness may be overestimated in:

Acute alcohol-associated hepatitis
Acute hepatic inflammation
Cholestasis
Hepatic congestion

Therefore, defer FibroScan until acute inflammation has resolved when possible.

Imaging for Hepatocellular Carcinoma Surveillance

Patients with cirrhosis due to ALD should undergo surveillance for HCC.

Recommended modality:

Abdominal ultrasound every 6 months, with or without serum alpha-fetoprotein (AFP), depending on local practice and guideline recommendations.

Diagnostic Criteria (NIAAA Consensus)

Diagnosis is primarily clinical with supporting laboratory findings .

Jaundice within the previous 8 weeks
Long-termfor ≥6 months-heavy alcohol use:

40 g/day (women)
60 g/day (men)

Alcohol use within the preceding 60 days
AST >50 IU/L
AST/ALT ratio >1.5(<1.5-think of alternate diagnosis)
AST and ALT both <400 IU/L
Total bilirubin >3 mg/dL
Exclusion of alternative diagnoses (e.g., drug-induced liver injury, ischemic hepatitis).

When is Liver Biopsy Needed?

Routine biopsy is not recommended.

Consider transjugular liver biopsy if:

Diagnosis is uncertain
Competing diagnoses exist
Corticosteroid therapy is being considered but diagnosis is unclear
Drug-induced liver injury, autoimmune hepatitis, or malignancy is suspected

Differential Diagnosis

Disease	Distinguishing Features
Acute viral hepatitis	AST/ALT often >1000 IU/L, viral serology positive
Drug-induced liver injury	Medication history, variable enzyme pattern
Ischemic hepatitis	Shock, AST/ALT often >1000 IU/L
Autoimmune hepatitis	ANA, ASMA, IgG elevated
Acute biliary obstruction	Marked ALP elevation, biliary dilatation on imaging
Acute-on-chronic liver failure	Identifiable precipitant with underlying cirrhosis
Wilson disease	Young age, low ceruloplasmin, hemolysis

Severity Assessment

Scoring System	Key Features / Interpretation
Maddrey Discriminant Function (MDF)	Formula: 4.6 × (PT<sub>patient</sub> − PT<sub>control</sub>) + Bilirubin (mg/dL). <32: Mild disease; ≥32: Severe alcoholic hepatitis with high short-term mortality; consider corticosteroids if no contraindications.
MELD Score	Preferred by recent guidelines; higher score indicates greater mortality risk. MELD ≥21 generally indicates severe disease.
MELD-Na	Incorporates serum sodium; often predicts mortality better than MELD alone.
ABIC Score	Uses Age, Bilirubin, INR, Creatinine; stratifies patients into low-, intermediate-, and high-riskmortality groups.
Glasgow Alcoholic Hepatitis Score (GAHS)	Uses Age, WBC, Urea, INR, Bilirubin; GAHS ≥9 indicates poor prognosis and may support corticosteroid therapy.
Lille Score	Calculated after 7 days (or day 4 in some centers) of corticosteroid therapy using Age, Albumin, Bilirubin (Day 0 & 7), Creatinine, INR. <0.45: Responder → Continue corticosteroids; ≥0.45:Non-responder → Stop corticosteroids.

Management

1. Complete Alcohol Abstinence

The single most important intervention.

Measures include:

Addiction counseling
Patients with AH are at risk of alcohol withdrawal. Lorazepam and oxazepam are the preferred benzodiazepines for prophylaxis and treatment of alcohol withdrawal.

2. Nutritional Therapy

Malnutrition is common.

Recommendations:

35–40 kcal/kg/day(nutritional supplementation preferably via mouth or NG tube should be considered if oral intake is less than 1200 kcal in a day.)
1.2–1.5 g protein/kg/day
Frequent meals
Late-evening snack
Enteral feeding if oral intake is inadequate
Vitamin supplementation:Thiamine—Folate—Pyridoxine—Vitamin D—Zinc—Magnesium (if deficient)

Protein restriction is not recommended unless temporarily required for severe uncontrolled encephalopathy.

When to give vitamin K

Vitamin K (usually 10 mg IV or slow IV/SC, depending on the clinical situation) is appropriate when there is suspected or confirmed vitamin K deficiency, such as:

Malnutrition (common in chronic alcohol use)
Prolonged poor oral intake
Cholestatic liver disease with fat-soluble vitamin malabsorption
Recent prolonged broad-spectrum antibiotic use
Before concluding that coagulopathy is solely due to liver failure

A common clinical approach is to administer 10 mg vitamin K daily for up to 3 days in patients with cirrhosis or alcohol-associated hepatitis when deficiency is suspected.

3. Infection Screening

Approximately one-quarter of patients have infection at presentation.

Perform:

Blood cultures
Urine culture
Chest radiograph
Diagnostic paracentesis if ascites is present
Appropriate cultures based on symptoms

Treat infections promptly; active uncontrolled infection is a contraindication to corticosteroids.

4. Corticosteroids(controversial)

Indications:

Severe alcoholic hepatitis (e.g., MDF ≥32 or MELD ≥21-American Gastroenterology Society guidelines )
No contraindications

Preferred regimen:Prednisolone 40 mg orally once daily for 28 days

If oral therapy is not feasible:Intravenous methylprednisolone 32 mg/day (equivalent glucocorticoid dose)

Assess response using the Lille score after 7 days (or day 4 in selected centers).

Contraindications include:

Active uncontrolled infection
Gastrointestinal bleeding
Acute kidney injury requiring caution
Severe pancreatitis
Uncontrolled diabetes or psychosis
Uncontrolled sepsis

5. N-Acetylcysteine (NAC)

Intravenous NAC for 5 days, combined with prednisolone( American Gastroenterology Guidelines recommend for patients with a MELD score >20 ), may improve short-term outcomes in selected patients with severe alcoholic hepatitis, but it is not recommended as monotherapy.

6. Pentoxifylline(controversial)

No longer recommended because randomized trials have not demonstrated a survival benefit.
400 mg orally, three times a day for 28 days
Many recent trials, including the STOPAH trial and meta-analysis of the use of steroids and Pentoxifylline, reveal only short-term (28-day) mortality improvements with not much difference of 6-month, or 1-year mortality.

7. Management of Complications

Treat according to standard cirrhosis and liver failure guidelines:

Ascites: sodium restriction, diuretics, large-volume paracentesis with albumin when indicated
Hepatic encephalopathy: lactulose ± rifaximin
Variceal bleeding: vasoactive drugs, endoscopic therapy, antibiotics
Hepatorenal syndrome: albumin plus vasoconstrictors (e.g., terlipressin where appropriate)
Acute kidney injury: optimize volume status, avoid nephrotoxins, renal replacement therapy if indicated
Coagulopathy: blood products only for bleeding or invasive procedures

8. Liver Transplantation

Consider in carefully selected patients with:

Severe alcoholic hepatitis not responding to medical therapy (e.g., high Lille score)
High predicted mortality
Favorable psychosocial evaluation and low relapse risk

Many centers no longer require a fixed 6-month abstinence period, instead using individualized multidisciplinary assessment.

Prognosis

Approximate mortality:

Severity	Mortality
Mild disease	<10% at 28 days
Severe disease	20–40% at 28 days
Steroid non-responders (high Lille score)	Up to 70% at 6 months

Causes of Death

Acute liver failure
Sepsis
Hepatorenal syndrome
Variceal bleeding
Multiorgan failure

References

Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey MR. Diagnosis and treatment of alcohol-associated liver diseases: 2024 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology. 2024.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of alcohol-related liver disease. J Hepatol. 2024.
Singal AK, Mathurin P. Diagnosis and treatment of alcohol-associated hepatitis. N Engl J Med. 2021;385:815-26.
O’Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Am J Gastroenterol. 2010;105:14-32. (Foundational ACG guideline; superseded in parts by newer guidance)
Jameson JL, Fauci AS, Kasper DL, et al., editors. Harrison’s Principles of Internal Medicine. 22nd ed. New York: McGraw-Hill; 2024.